




		EMLc	ATC codes: <a href="#">N07AA01</a>
Indication	Myasthenia gravis	ICD11 code: <a href="#">8C70.Z</a>	
INN	Neostigmine bromide		
Medicine type	Chemical agent		
List type	Core (EML) (EMLc)		
Formulations	Parenteral > General injections > unspecified: 0.5 mg per mL in 1 mL ampoule (neostigmine metilsulfate) ; 2.5 mg per mL in 1 mL ampoule (neostigmine metilsulfate) Oral > Solid > tablet: 15 mg (neostigmine bromide) (EML)		
EML status history	First added in 1977 ( <a href="#">TRS 615</a> ) Changed in 1979 ( <a href="#">TRS 641</a> ) Changed in 1989 ( <a href="#">TRS 796</a> ) Changed in 2003 ( <a href="#">TRS 920</a> ) Changed in 2007 ( <a href="#">TRS 950</a> ) Changed in 2025 ( <a href="#">TRS 1064</a> )		
Sex	All		
Age	Also recommended for children		
Therapeutic alternatives	The recommendation is for this specific medicine		
Patent information	Patents have expired in most jurisdictions Read more <a href="#">about patents</a> . 		
Wikipedia	<a href="#">Neostigmine</a> 		
DrugBank	<a href="#">Neostigmine</a> 		

## Summary of evidence and Expert Committee recommendations

Following the review of the age-appropriateness of formulations on the EMLc, the Expert Committee recommended: - the deletion of neostigmine 15 mg tablets from the EMLc

